The role of endothelial nitric oxide synthase in the pathogenesis of essential hypertension
https://doi.org/10.52485/19986173_2023_1_165
Abstract
Essential hypertension is a complex disease determined by the interaction of genetic and environmental factors. This review provides information on the nitric oxide, nitric oxide synthase. Current data on the role of endothelial nitric oxide synthase in the development of arterial hypertension are presented.
Keywords
nitric oxide,
nitric oxide synthase,
nitric oxide synthase,
essential hypertension,
primary hypertension,
endothelial dysfunction
Supporting agencies: The study had no financial support
About the Authors
V. A. Mikhno
Chita Sate Medical Academy
Russian Federation
Russian Federation
672000; 39A, Gorky str.; Chita
I. K. Bogomolova
Chita Sate Medical Academy
Russian Federation
Russian Federation
672000; 39A, Gorky str.; Chita
References
1. Vas'kina E.A. Arterial hypertension: oxidative stress and endothelial dysfunction [dissertation]. Novosibirsk. Novosibirsk State Medical University. 2004. in Russian.
2. Veresh Z., Racz A., Lotz G., Koller A. ADMA impairs nitric oxide-mediated arteriolar function due to increased superoxide production by angiotensin II-NAD(P)H oxidase pathway. Hypertension. 2008. 52(5). 960-966. DOI: 10.1161/HYPERTENSIONAHA.108.116731.
3. Ding J., Yu M., Jiang J., Luo Y., Zhang Q., Wang S., Yang F., Wang A., Wang L., Zhuang M., Wu S., Zhang Q., Xia Y., Lu D. Angiotensin II Decreases Endothelial Nitric Oxide Synthase Phosphorylation via ATR Nox/ROS/PP2A Pathway. Front Physiol. 2020 Sep 11. a566410. DOI: 10.3389/fphys.2020.566410.
4. Gzogjan M.N. The effect of long-term controlled cycling with α1-, β1–, β2-adrenoblockade and ACE inhibition on the regression of heart failure and endothelial dysfunction in patients with myocardial infarction [dissertation]. Tomsk NRMC Cardiology research institute. 2005. in Russian.
5. Lermontova N.Ju. Clinical and prognostic value of indicators of endothelial dysfunction and aggregation of platelets in patients with acute ischemic disease of heart [dissertation]. Tomsk NRMC Cardiology research institute. 2005. in Russian.
6. Popova A.A. Early markers of endothelial dysfunction in young people with arterial hypertension [dissertation]. Novosibirsk. Novosibirsk State Medical University. 2004. in Russian.
7. Zhuo J.L., Mendelsohn F.A., Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension. 2002 Feb. 39(2). 634-638. DOI: 10.1161/hy0202.103417.
8. Garcia V., Sessa W.C. Endothelial NOS: perspective and recent developments. Br J Pharmacol. 2019 Jan. 176(2). 189-196. DOI: 10.1111/bph.14522.
9. Daiber A., Xia N., Steven S., Oelze M., Hanf A., Kröller-Schön S., Münzel T., Li H. New Therapeutic Implications of Endothelial Nitric Oxide Synthase (eNOS) Function/Dysfunction in Cardiovascular Disease. Int J Mol Sci. 2019 Jan. 20(1). 187. DOI: 10.3390/ijms20010187.
10. Farah C., Michel L.Y.M., Balligand J.L. Nitric oxide signalling in cardiovascular health and disease. Nat Rev Cardiol. 2018 May. 15(5). 292-316. DOI: 10.1038/nrcardio.2017.224.
11. Suvorava T., Metry S., Pick S., Kojda G. Alterations in endothelial nitric oxide synthase activity and their relevance to blood pressure. Biochem Pharmacol. 2022 Nov. 205. 115256. DOI: 10.1016/j.bcp.2022.115256.
12. Pautz A., Li H., Kleinert H. Regulation of NOS expression in vascular diseases. Front Biosci (Landmark Ed). 2021 Apr. 26(5). 85-101. DOI: 10.52586/4926.
13. Alderton W.K., Cooper C.E., Knowles R.G. Nitric oxide synthases: structure, function and inhibition. Biochem J. 2001 Aug. 357(3). 593-615. DOI: 10.1042/0264-6021:3570593.
14. Kourosh-Arami M., Hosseini N., Mohsenzadegan M., Komaki A., Joghataei M.T. Neurophysiologic implications of neuronal nitric oxide synthase. Rev Neurosci. 2020 Aug. 31(6). 617-636. DOI: 10.1515/revneuro-2019-0111.
15. Tran N., Garcia T., Aniqa M., Ali S., Ally A., Nauli S.M. Endothelial Nitric Oxide Synthase (eNOS) and the Cardiovascular System: in Physiology and in Disease States. Am J Biomed Sci Res. 2022. 15(2). 153-177. DOI: 10.34297/AJBSR.2022.15.002087.
16. Ally A., Powell I., Ally M.M., Chaitoff K., Nauli S.M. Role of neuronal nitric oxide synthase on cardiovascular functions in physiological and pathophysiological states. Nitric Oxide. 2020 Sep. 102. 52-73. DOI: 10.1016/j.niox.2020.06.004.
17. Zhang T., Guo D., Zheng W., Dai Q. Effects of S1PR2 antagonist on blood pressure and angiogenesis imbalance in preeclampsia rats. Mol Med Rep. 2021 Jun. 23(6). 456. DOI: 10.3892/mmr.2021.12095.
18. Eid S.A., Hinder L.M., Zhang H., Eksi R., Nair V., Eddy S., Eichinger F., Park M., Saha J., Berthier C.C., Jagadish H.V., Guan Y., Pennathur S., Hur J., Kretzler M., Feldman E.L., Brosius F.C. Gene expression profiles of diabetic kidney disease and neuropathy in eNOS knockout mice: Predictors of pathology and RAS blockade effects. FASEB J. 2021 May. 35(5). e21467. DOI: 10.1096/fj.202002387R.
19. Ninchoji T., Love D.T., Smith R.O., Hedlund M., Vestweber D., Sessa W.C., Claesson-Welsh L. eNOS-induced vascular barrier disruption in retinopathy by c-Src activation and tyrosine phosphorylation of VE-cadherin. Elife. 2021 Apr. 10. e64944. DOI: 10.7554/eLife.64944.
20. García-Martín E., Navarro-Muñoz S., Rodriguez C., Serrador M., Alonso-Navarro H., Calleja M., Turpín-Fenoll L., Recio-Bermejo M., García-Ruiz R., Millán-Pascual J., Navacerrada F., Plaza-Nieto J.F., García-Albea E., Agúndez J.A.G., Jiménez-Jiménez F.J. Association between endothelial nitric oxide synthase (NOS3) rs2070744 and the risk for migraine. Pharmacogenomics J. 2020 Jun. 20(3). 426-432. DOI: 10.1038/s41397-019-0133-x.
21. Modena M., Vecoli C., Caselli C., Todiere G., Poddighe R., Valente S., Bandini F., Natali A., Ghiadoni L., Clerico A., Vittorini S., Botto N., Andreassi M.G., Emdin M., Neglia D. Association of eNOS Glu298Asp polymorphism with cardiometabolic risk and inducible myocardial ischemia in patients with stable coronary artery disease. European Heart Journal. 2022. 43(2). DOI: 10.1093/eurheartj/ehac544.1112.
22. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021. 398(10304). 957-980. DOI: 10.1016/S0140-6736(21)01330-1.
23. Tsao C.W., Aday A.W., Almarzooq Z.I., et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022. 145(8). 153-639. DOI: 10.1161/CIR.0000000000001052.
24. Morbidity of the population by the main classes of diseases in 2000-2021. The Federal State Statistics Service of the Ministry of Economic Development of the Russian Federation. Available from: https://rosstat.gov.ru/folder/13721. in Russian.
25. Śladowska-Kozłowska J., Litwin M., Niemirska A., Wierzbicka A., Roszczynko M., Szperl M. Associations of the eNOS G894T gene polymorphism with target organ damage in children with newly diagnosed primary hypertension. Pediatr Nephrol. 2015 Dec. 30(12). 2189-2197. DOI: 10.1007/s00467-015-3164-9.
26. Nassereddine S., Hassani Idrissi H., Habbal R., Abouelfath R., Korch F., Haraka M., Karkar A., Nadifi S. The polymorphism G894 T of endothelial nitric oxide synthase (eNOS) gene is associated with susceptibility to essential hypertension (EH) in Morocco. BMC Med Genet. 2018 Jul. 19(1). 127. DOI: 10.1186/s12881-018-0638-1.
27. Abbasi H., Dastgheib S.A., Hadadan A., Karimi-Zarchi M., Javaheri A., Meibodi B., Zanbagh L., Tabatabaei R.S., Neamatzadeh H. Association of Endothelial Nitric Oxide Synthase 894G > T Polymorphism with Preeclampsia Risk : A Systematic Review and Meta-Analysis based on 35 Studies. Fetal Pediatr Pathol. 2021 Oct. 40(5). 455-470. DOI: 10.1080/15513815.2019.1710880.
28. Inácio A., Aguiar L., Bicho M., Freitas J., Faustino P., Matos A., Menezes Falcão L. Interplay between glycemia and the genetics of eNOS and ACE for the susceptibility to the onset and development of hypertension on the Portuguese population. Gene Reports. 2021. 22(1–2). DOI: 10.1016/j.genrep.2020.100975.
29. Shi J., Liu S., Guo Y., Liu S., Xu J., Pan L., Hu Y., Liu Y., Cheng Y. Association between eNOS rs1799983 polymorphism and hypertension: a meta-analysis involving 14,185 cases and 13,407 controls. BMC Cardiovasc Disord. 2021 Aug. 21(1). 385. DOI: 10.1186/s12872-021-02192-2.
30. Xu X., Ye W., Chen H., Liu M., Jiang W., Fang Z. Association of endothelial nitric oxide synthase intron 4a/b gene polymorphisms and hypertension : a systematic review and meta-analysis. Journal of International Medical Research. 2021. 49(3). 1–14. DOI: 10.1177/0300060520979230.
31. Jiang S., Yang G., Zhou S., Zhang X., Peng C., Lu Q. Bisphenol A, S, and F exposure, ESR1/2, CAT, and eNOS genetic polymorphisms, and the risk of hypertension. Ecotoxicol Environ Saf. 2021 Aug. 224:112684. DOI: 10.1016/j.ecoenv.2021.112684.
32. Chenou F., Albuquerque D.M., Leonardo D.P., Domingos I.F., Bezerra M.A.C., Araújo A.S., Blotta M.H.S.L., Costa F.F., Sonati M.F., Paula E.V., Santos M.N.N.. Endothelial Nitric Oxide Synthase (eNOS) Gene Polymorphisms and Markers of Hemolysis, Inflammation and Endothelial Dysfunction in Brazilian Sickle Cell Anemia Patients. Biochem Genet. 2020 Aug, 58(4). 580-594. DOI: 10.1007/s10528-020-09959-w.
33. Chen J., Shi M., Wang N., Yi P., Sun L., Meng Q. TSH inhibits eNOS expression in HMEC-1 cells through the TSHR/PI3K/AKT signaling pathway. Ann Endocrinol (Paris). 2019 Nov. 80(5-6). 273-279. DOI: 10.1016/j.ando.2019.06.007.
34. Couto G.K., Paula S.M., Gomes-Santos I.L., Negrão C.E., Rossoni L.V. Exercise training induces eNOS coupling and restores relaxation in coronary arteries of heart failure rats. Am J Physiol Heart Circ Physiol. 2018 Apr. 314(4). H878-H887. DOI: 10.1152/ajpheart.00624.2017.
35. Marino F., Scalise M., Cianflone E., Salerno L., Cappetta D., Salerno N., De Angelis A., Torella D., Urbanek K.. Physical Exercise and Cardiac Repair: The Potential Role of Nitric Oxide in Boosting Stem Cell Regenerative Biology. Antioxidants (Basel). 2021 Jun. 10(7). 1002. DOI: 10.3390/antiox10071002.
36. Khalaf D., Krüger M., Wehland M., Infanger M., Grimm D. The Effects of Oral l-Arginine and l-Citrulline Supplementation on Blood Pressure. Nutrients. 2019 Jul. 11(7). 1679. DOI: 10.3390/nu11071679.
37. Barkhidarian B., Khorshidi M., Shab-Bidar S., Hashemi B. Effects of L-citrulline supplementation on blood pressure: A systematic review and meta-analysis. Avicenna J Phytomed. 2019 Jan-Feb. 9(1). 10-20.
Review
For citations:
Mikhno V.A., Bogomolova I.K. The role of endothelial nitric oxide synthase in the pathogenesis of essential hypertension. Transbaikalian Medical Bulletin. 2023;(1):165-172. (In Russ.) https://doi.org/10.52485/19986173_2023_1_165
Views:
122
Email this article 